David Hay — Friday POW!: Incyte (INCY)

The frame — a base case that pays for the option

• The pick is built in two halves that are deliberately kept separate. "The bull case is a company in the midst of a commercial and pipeline inflection that the market has partially recognized but we don't think has fully priced" — that is the half you pay for. "And specifically what is being said about the KRAS G12D data" — that is the half the house argues you get for free.
• The engine is named in one line each: "Jakafi is the cash cow, while Opzelura is the growth driver that has consistently outrun consensus estimates," with "four anticipated product approvals in the next 12 months" as "the near-term catalysts" and "ten Phase 3 studies underway" as "the pipeline depth that simultaneously provides optionality across multiple disease areas."
• All data is stamped as of 9/2, two days before publication — the house's usual practice of dating the numbers rather than the opinion.

The quarter — a 68% beat, and the honest version of it

• Q2 2026 (reported July 28): revenue $1.67B, +38% YoY; net sales $1.49B, +40%; EPS $3.09 against a $1.84 consensus — a 68% beat.
• The beat is immediately deflated by its own author: it "included a $246 million non-cash Medicaid rebate settlement. Stripping that out, the operational beat was approximately 55% against the $1.99 adjusted consensus" — still a very large beat, but the disclosed number is the smaller one.
• Guidance moved with it: FY2026 net sales raised to $5.13–$5.26B, with the EPS consensus at ~$7.50 (an estimated +106% YoY).

Jakafi — the cash cow, and the cliff attached to it

• "Jakafi remains the dominant treatment for myelofibrosis, polycythemia vera, and graft-versus-host disease." Q2 net sales of $817M put it "on pace for approximately $3.2 billion annually, shared with Novartis outside the U.S."
• The bear case is raised in the same breath rather than deferred: "U.S. compound patent protection runs through 2028, with formulation patents potentially extending exclusivity to 2033… The patent cliff is real and is the primary structural bear case."
• The answer offered is time already spent, not a projection: "Incyte has spent five years building the commercial depth to manage this transition rather than absorb a cliff."

Opzelura — the evidence the transition is already underway

• $450M in Q2 net sales "is evidence that this shift is already underway." Approved for atopic dermatitis in 2021 and vitiligo in 2022, it is "the first and still the only FDA-approved treatment that can restore skin color in vitiligo patients," and "has consistently exceeded the most optimistic consensus estimates."
• The economics of label expansion are the point: it "is far down the trial pathways for treating other types of skin disease," and "each approved indication adds a new patient population at minimal marginal cost" — growth without a matching cost line.

KRAS G12D — why the house thinks this one is different

• The disease is described before the drug: PDAC "kills more reliably than almost any other major cancer," with five-year survival "below 12% for all stages, below 3% for metastatic disease," and KRAS mutations in ~90% of cases "that were considered undruggable for three decades."
• The precedent that de-risks the mechanism: "KRAS G12C inhibitors in lung cancer proved the mechanism could work in humans; KRAS G12D — present in approximately 40% of pancreatic cancers — is the next frontier."
• The data: DAWN-303 EU registry — with GemNabP, "a 62.5% response rate and a 95.8% disease control rate"; with mFOLFIRINOX, "75% response rate, 100% disease control rate" — against first-line chemotherapy alone at "20% to 30%." Verdict: "less of a lottery ticket and more of a practice-changing drug."
• The test date and the downside are both named: RBC calls the ESMO update "likely to be very competitive," and the October oral presentation "will confirm or challenge this reading." If it fails, "Incyte absorbs it from a diversified multi-franchise platform rather than a binary single-asset position" — the diversification is what makes the option affordable.

Valuation — and the arithmetic that says the option is free

• ~16.5x the 2026 EPS consensus of ~$7.50. On enterprise value: ~$22.4B (cap less $4B net cash) against $5.2B of guided FY sales = "approximately 4.3x EV/revenue, which is modest for a business growing net sales 40% year-over-year."
• The Price/Sales cross-check is volunteered with its weakness first — the "headline ~4.4x price-to-sales ratio looks only moderately cheap" — and then corrected: the "~$4.5B cash pile reduces the more meaningful EV/sales multiple to ~3.6x," which for "a highly profitable biopharma growing underlying product sales at double digits with a deep Phase III pipeline… we view as pretty attractively valued."
• The consensus target is read as a disclosure, not a forecast: $127.13 "is essentially at the current price, which suggests the consensus model is a Jakafi-plus-Opzelura base case with limited KRAS credit," while Leerink/Canaccord/H.C. Wainwright at $150–155 "are the analysts adding in KRAS optionality." Conclusion: "the market is paying almost nothing for a program that is showing 62% to 75% response rates in one of the most lethal cancers in existence."
• The stated reason for the discount is put plainly: it "largely reflects the fear that its newer products won't replace its legacy ones" — i.e. the same patent cliff, priced.

Technicals — late to the breakout, and saying so

• "Frankly, we are a bit late to this one from a timely breakout signal standpoint" — the signal fired "late last year when it initially broke into the $90s," above the ~$85 shelf that had capped the stock since 2021.
• Why being late is tolerable here: "the appreciation since then hasn't been excessive and, encouragingly, it's been earnings-driven per the above profits data" — the multiple did the following, not the leading (the five-year chart shows P/E ~17.8 and P/S ~4.4 versus a 2021 peak near 22x and 6x).
• The entry instruction is a wait, not a chase: it is "somewhat stretched over the 200-day moving average," so "a retracement back to $110 or so would not be at all surprising. More conservative investors might want to hold off to see if that happens."

Arguing the other side — the cliff, the cut, and the run

• The cliff, sized: "Jakafi at $817 million quarterly is approximately 55% of current net sales, and a meaningful portion of that revenue is at risk"; generics "could begin as early as [2028] in a scenario where formulation patents do not extend exclusivity." The failure mode is specific: "Opzelura and the new product launches grow too slowly to offset genericization."
• The data caveat: the KRAS numbers come "from a small interim cut with maturity limitations," the registrational trial "is randomized and placebo-controlled," and "Phase 1 combination data has misled markets before." Durability and long-term safety "are also not yet available."
• The price caveat: "the stock at $129 with 49% 12-month appreciation is not a margin-of-safety purchase. A KRAS ESMO miss or any regulatory stumble on the four anticipated approvals hits a stock priced for continued execution with limited consensus upside buffer."
• The rebuttal is a restatement of the asymmetry rather than a denial: "at 4.3x EV/revenue on 40% sales growth, $4 billion in net cash, and KRAS data that multiple analysts have described as potentially game-changing, the current price embeds almost no credit for the upside scenario."

The bottom line — a sleeve, not a one-off

• The pick is positioned as sector construction: "adding Incyte to the Haymaker portfolio is the continuation of the healthcare sleeve we started building with the inclusions of MDT and DGX in early June, as well as GILD a month ago. We believe healthcare and biotech are entering (or are in) a bullish recovery mode that will continue for the foreseeable future."
• The summary of what is being bought: "the largest independent JAK inhibitor franchise in the world at $817 million per quarter, the fastest-growing dermatology drug in the U.S. at $450 million per quarter (with label expansions in four additional indications pending), and drugs that are in 10 Phase 3 studies. As a kicker, the company has a KRAS G12D inhibitor showing extraordinary response rates in first-line pancreatic cancer."
• The verdict, unhedged: "We recommend a Buy on INCY." Balance-sheet support is noted alongside — "$4.0B+ net cash; no meaningful debt," which "supports pipeline and M&A" — and the calendar is ESMO in October then earnings October 27. No dividend; beta ~0.41.